The bone marrow-cardiac axis

Role of endothelial progenitor cells in heart failure

Simon Maltais, Louis P. Perrault, Hung Q. Ly

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Congestive heart failure (CHF) remains a leading cause of mortality in the developed world. The complex mechanisms involved in the pathophysiology of heart failure (HF) explain some of the limited impact of current recognised therapeutic strategies. There is, therefore, a definite need for new alternative molecular and biological pathways to address the treatment of this condition. Over the past decade, much research has focussed upon identifying the ideal cell type to promote myocardial regeneration. Recently, striking reports suggested the concept that bone-marrow (BM)-derived endothelial progenitor cells (EPCs) participate in cardiac regeneration and function recovery in the setting of progressive HF. The modulation of this complex interaction between the BM and the circulating EPCs could be at the crossroad of multiple therapeutic strategies aimed to protect or restore the myocardium in the setting of the CHF. However, there are uncertainties and unresolved issues regarding the mechanisms possibly responsible for the functional benefits observed in chronic experimental and pre-clinical studies. Hence, the BM-cardiac axis concept has created overwhelming enthusiasm and subsequent scepticism in the field of cardiac repair and regeneration. Further intensive research in basic science and clinical arenas are needed to elucidate the potential association between BM and heart function recovery, particularly in the progression towards advance stages of CHF. In this review, we focus on the importance of the BM-cardiac axis and BM-derived EPCs in the pathophysiology, clinical progression and potential treatment of CHF.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalEuropean Journal of Cardio-thoracic Surgery
Volume39
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Heart Failure
Bone Marrow
Regeneration
Recovery of Function
Research
Uncertainty
Endothelial Progenitor Cells
Myocardium
Mortality
Therapeutics

Keywords

  • Bone marrow axis
  • Heart failure
  • Progenitor cells
  • Therapy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

The bone marrow-cardiac axis : Role of endothelial progenitor cells in heart failure. / Maltais, Simon; Perrault, Louis P.; Ly, Hung Q.

In: European Journal of Cardio-thoracic Surgery, Vol. 39, No. 3, 01.03.2011, p. 368-374.

Research output: Contribution to journalReview article

@article{1506e242f79541ec90e72619c8cba3ac,
title = "The bone marrow-cardiac axis: Role of endothelial progenitor cells in heart failure",
abstract = "Congestive heart failure (CHF) remains a leading cause of mortality in the developed world. The complex mechanisms involved in the pathophysiology of heart failure (HF) explain some of the limited impact of current recognised therapeutic strategies. There is, therefore, a definite need for new alternative molecular and biological pathways to address the treatment of this condition. Over the past decade, much research has focussed upon identifying the ideal cell type to promote myocardial regeneration. Recently, striking reports suggested the concept that bone-marrow (BM)-derived endothelial progenitor cells (EPCs) participate in cardiac regeneration and function recovery in the setting of progressive HF. The modulation of this complex interaction between the BM and the circulating EPCs could be at the crossroad of multiple therapeutic strategies aimed to protect or restore the myocardium in the setting of the CHF. However, there are uncertainties and unresolved issues regarding the mechanisms possibly responsible for the functional benefits observed in chronic experimental and pre-clinical studies. Hence, the BM-cardiac axis concept has created overwhelming enthusiasm and subsequent scepticism in the field of cardiac repair and regeneration. Further intensive research in basic science and clinical arenas are needed to elucidate the potential association between BM and heart function recovery, particularly in the progression towards advance stages of CHF. In this review, we focus on the importance of the BM-cardiac axis and BM-derived EPCs in the pathophysiology, clinical progression and potential treatment of CHF.",
keywords = "Bone marrow axis, Heart failure, Progenitor cells, Therapy",
author = "Simon Maltais and Perrault, {Louis P.} and Ly, {Hung Q.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.ejcts.2010.04.022",
language = "English (US)",
volume = "39",
pages = "368--374",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The bone marrow-cardiac axis

T2 - Role of endothelial progenitor cells in heart failure

AU - Maltais, Simon

AU - Perrault, Louis P.

AU - Ly, Hung Q.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Congestive heart failure (CHF) remains a leading cause of mortality in the developed world. The complex mechanisms involved in the pathophysiology of heart failure (HF) explain some of the limited impact of current recognised therapeutic strategies. There is, therefore, a definite need for new alternative molecular and biological pathways to address the treatment of this condition. Over the past decade, much research has focussed upon identifying the ideal cell type to promote myocardial regeneration. Recently, striking reports suggested the concept that bone-marrow (BM)-derived endothelial progenitor cells (EPCs) participate in cardiac regeneration and function recovery in the setting of progressive HF. The modulation of this complex interaction between the BM and the circulating EPCs could be at the crossroad of multiple therapeutic strategies aimed to protect or restore the myocardium in the setting of the CHF. However, there are uncertainties and unresolved issues regarding the mechanisms possibly responsible for the functional benefits observed in chronic experimental and pre-clinical studies. Hence, the BM-cardiac axis concept has created overwhelming enthusiasm and subsequent scepticism in the field of cardiac repair and regeneration. Further intensive research in basic science and clinical arenas are needed to elucidate the potential association between BM and heart function recovery, particularly in the progression towards advance stages of CHF. In this review, we focus on the importance of the BM-cardiac axis and BM-derived EPCs in the pathophysiology, clinical progression and potential treatment of CHF.

AB - Congestive heart failure (CHF) remains a leading cause of mortality in the developed world. The complex mechanisms involved in the pathophysiology of heart failure (HF) explain some of the limited impact of current recognised therapeutic strategies. There is, therefore, a definite need for new alternative molecular and biological pathways to address the treatment of this condition. Over the past decade, much research has focussed upon identifying the ideal cell type to promote myocardial regeneration. Recently, striking reports suggested the concept that bone-marrow (BM)-derived endothelial progenitor cells (EPCs) participate in cardiac regeneration and function recovery in the setting of progressive HF. The modulation of this complex interaction between the BM and the circulating EPCs could be at the crossroad of multiple therapeutic strategies aimed to protect or restore the myocardium in the setting of the CHF. However, there are uncertainties and unresolved issues regarding the mechanisms possibly responsible for the functional benefits observed in chronic experimental and pre-clinical studies. Hence, the BM-cardiac axis concept has created overwhelming enthusiasm and subsequent scepticism in the field of cardiac repair and regeneration. Further intensive research in basic science and clinical arenas are needed to elucidate the potential association between BM and heart function recovery, particularly in the progression towards advance stages of CHF. In this review, we focus on the importance of the BM-cardiac axis and BM-derived EPCs in the pathophysiology, clinical progression and potential treatment of CHF.

KW - Bone marrow axis

KW - Heart failure

KW - Progenitor cells

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79951512405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951512405&partnerID=8YFLogxK

U2 - 10.1016/j.ejcts.2010.04.022

DO - 10.1016/j.ejcts.2010.04.022

M3 - Review article

VL - 39

SP - 368

EP - 374

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 3

ER -